Brief: Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
05/03/2025 22:25
March 5 (Reuters) - Aquestive Therapeutics Inc AQST.O: AQUESTIVE THERAPEUTICS, INC. Q4 ADJUSTED EBITDA USD -11.029 MILLION AQUESTIVE THERAPEUTICS, INC. Q4 PRETAX PROFIT USD -17.069 MILLION VERSUS. IBES ESTIMATE USD -12.7 MILLION AQUESTIVE THERAPEUTICS, INC. Q4 INCOME FROM OPERATIONS USD -13.579 MILLION VERSUS. IBES ESTIMATE USD -9.57 MILLION AQUESTIVE THERAPEUTICS, INC. Q4 NET INCOME USD -17.055 MILLION VERSUS. IBES ESTIMATE USD -12.8 MILLION AQUESTIVE THERAPEUTICS, INC. Q4 REVENUE USD 11.867 MILLION VERSUS. IBES ESTIMATE USD 13.1 MILLION : QTRLY LOSS PER SHARE $0.19 OUTLOOK FY TOTAL REVENUE $47MLN TO $56 MILLION FY2025 REVENUE VIEW $53.0 MILLION -- LSEG IBES DATA Source text: ID:nGNX86ffCW Further company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million